NCT03807999View on ClinicalTrials.gov

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

February 19, 2015

Primary Completion Date

April 1, 2018

Study Completion Date

November 1, 2018

Conditions
Pancreatic Neoplasm
Interventions
DRUG

Nab-paclitaxel

DRUG

Gemcitabine

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Hacettepe University

OTHER

NCT03807999 - Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer | Biotech Hunter | Biotech Hunter